Use of disease-modifying therapies on the rise in SCD: US study

Chronic blood transfusion therapy use remained low over 8-year period

The use of pharmaceutical disease-modifying therapies (pDMTs) has increased in recent years among both children and adults with sickle cell disease (SCD), according to a study analyzing U.S. claims data.

Over the same eight-year period, the use of chronic blood transfusion therapy (CBT) has remained low and has been concentrated mainly among those with the most severe SCD-related complications.